Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 tralokinumab trial in atopic dermatitis with deep molecular phenotyping
2020-005976-36Phase 3Active
- Sponsor
- Karolinska University Hospital
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tralokinumab in atopic dermatitis (AD), sponsored by Karolinska University Hospital. Primary endpoint: Change from baseline in Body Surface Area (BSA) at 16 weeks of treatment. Started Mar 2021; status: active.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2020-005976-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005976-36.